Strategic merger Medimaps Group merged with Radiobotics ApS in March 2026, creating a larger AI-driven MSK radiology capability. This presents expanded cross-sell opportunities to Radiobotics’ existing customers and a broader product integration path for joint solutions.

Expanded clinical adoption TBS Osteo is already widely used across 90 countries with over 4.5 million procedures annually and has Medicare reimbursement in the US. Leverage this proven clinical footprint to target hospitals and clinics seeking established AI bone health solutions and reimbursement-ready workflows.

New software advances Recent launches such as TBS Reveal and AI-based image processing enhancements indicate ongoing product development. This creates upsell potential for current users to upgrade to advanced analytics and reveal capabilities, as well as differentiation when meeting customer requests for cutting-edge bone health imaging.

Public sector traction Medimaps’ reimbursement approval in the United States and activity at major radiology events (RSNA) signal strong credibility. Engage with hospital systems and payers emphasizing proven cost efficiency, fracture risk prediction, and workflow integration to drive procurement conversations.

Strategic partnerships Collaborations such as spine health research with Mayo Clinic and ongoing academic-industry engagements position Medimaps to pursue co-development, clinical studies, and regional pilots. Target large health networks and research institutes for joint studies and deployment of AI-driven bone health tools.